ESOC 2026 | Key trials presented at ESOC 2026
Aristeidis Katsanos, MD, PhD, McMaster University, Hamilton, Canada, outlines the key trials presented at ESOC 2026. He mentions the HOPE (NCT04892511), TECNO (NCT05499832), GALLOP (NCT06788626), and OCEANIC (NCT05686070) trials. This interview took place at the 12th European Stroke Organisation Conference (ESOC) in Maastricht, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, very exciting stuff. So most of the trials that are presented at ESOC, they have to do with thrombectomy. So HOPE is about the blood pressure control after thrombectomy, very exciting and still an open topic. Also, the TECNO trial is testing adjunct intra-arterial tenecteplase for people that they don’t recanalize completely after thrombectomy. There are other trials, such as the GALLOP trial, which is very close to my research interest, testing GLP-1 receptor agonists for improving patient outcomes...
Yeah, very exciting stuff. So most of the trials that are presented at ESOC, they have to do with thrombectomy. So HOPE is about the blood pressure control after thrombectomy, very exciting and still an open topic. Also, the TECNO trial is testing adjunct intra-arterial tenecteplase for people that they don’t recanalize completely after thrombectomy. There are other trials, such as the GALLOP trial, which is very close to my research interest, testing GLP-1 receptor agonists for improving patient outcomes. And there is also a very nice result from the OCEANIC stroke trial presented by one of my colleagues and PI of the trial, Dr Mike Sharma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
